Kuva Labs pushes tender offer for Lisata Therapeutics to July 20, with 64.67% of shares now tendered
LSTA has more than doubled off its 52-week low of $1.81.
Summary
Kuva Labs extended its $4.00/share tender offer for Lisata Therapeutics to July 20, 2026, with 64.67% of shares tendered so far. The merger outside date was also pushed to July 21, marking another delay in a deal critical to Lisata's survival.
Key Events · M&A and Partnerships · LSTA
-
Tender Offer Extended Again
The expiration time has been pushed to 11:59 p.m. ET on July 20, 2026, from July 16, and the merger outside date extended to July 21, 2026.
-
64.67% of Shares Tendered
As of July 15, 2026, approximately 5,897,848 shares have been validly tendered, representing 64.67% of the 9,119,742 outstanding shares.
-
Deal Still Faces Uncertainty
The tender offer has been repeatedly delayed since June 2026; Lisata carries a going concern warning and needs the merger to close to avoid potential insolvency.
-
Next Deadline: July 20
The offer now expires on July 20, 2026; if the minimum tender condition is met, closing is expected promptly thereafter.
Analysis · LSTA · Life Sciences
Kuva Labs has once again extended its tender offer for Lisata Therapeutics, moving the expiration to July 20, 2026, and the merger outside date to July 21. As of July 15, approximately 64.67% of outstanding shares have been tendered—closer to the minimum condition but still not enough to close. The repeated delays, set against a going concern warning and earlier postponements, highlight the deal's fragility. Should the tender fail, Lisata faces an uncertain future with dwindling cash.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 29.1% of the 1703 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LSTA was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.9M. The 52-week trading range was $1.81 to $5.07. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.